Use and safety of remdesivir in kidney transplant recipients with COVID-19
| العنوان: | Use and safety of remdesivir in kidney transplant recipients with COVID-19 |
|---|---|
| المؤلفون: | Maria Luisa Martin, Cristina Canal, Carlos Arias-Cabrales, Antonio Franco, Francesc Moreso, Isabel María Saura, Luis Sanchez-Cámara, Sofía Zárraga, Sheila Cabello Pelegrin, Julio Pascual, Emilio Sánchez-Álvarez, Inmaculada Lorenzo, Anna Buxeda, Raquel Santana-Estupiñán, Edoardo Melilli, María José Aladrén, Esperanza Moral Berrio, Judit Cacho, Marta Crespo, Orlando Siverio, Auxiliadora Mazuecos, José Portolés, Verónica López, Elena González-García, Paloma L Martin-Moreno, Iñigo Moina, María José Pérez-Sáez, Cristina Galeano, María del Carmen Ruiz-Fuentes |
| المساهمون: | Institut Català de la Salut, [Buxeda A, Arias-Cabrales C, Pérez-Sáez MJ] Department of Nephrology, Hospital del Mar, Institute Mar for Medical Research (IMIM), Red de Investigación Renal (REDinREN) (RD16/0009/0013), Barcelona, Spain. [Cacho J] Department of Nephrology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Cabello Pelegrin S] Department of Nephrology, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Melilli E] Department of Nephrology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain. [Moreso F] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Dipòsit Digital de la UB Universidad de Barcelona Scientia Kidney International Reports Repositorio Abierto de la UdL Universitad de Lleida |
| بيانات النشر: | Elsevier, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::lesión renal aguda [ENFERMEDADES], medicine.medical_treatment, Trasplantament renal, Remdesivir, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Injury, Other subheadings::Other subheadings::/drug therapy [Other subheadings], law.invention, Kidney transplantation, SARS-CoV2l, Randomized controlled trial, COVID-19 (Malaltia) - Tractament, law, Clinical Research, Internal medicine, medicine, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Adverse effect, business.industry, SARS-CoV-2, Acute kidney injury, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Immunosuppression, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], medicine.disease, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Acute Kidney Injury [DISEASES], Discontinuation, Insuficiència renal aguda, Nephrology, SARS-CoV2, Cohort, Avaluació de resultats (Assistència sanitària), Acute kidney, business, Cohort study |
| الوصف: | Introduction:Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time torecovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acutekidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidneytransplant recipients.Methods:We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treatedwith remdesivir. Outcomes and safety were assessed.Results:Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) requiredmechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged$65 years(45% vs. 3.2% in younger patients). Acute kidneyinjury was present in 27.7% of patients, but wasdiagnosed in 50% before treatment. No patients required remdesivir discontinuation because ofadverse events. We did notfind significant hepatoxicity or systemicsymptoms resulting from thedrug. Conclusion:In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renaland hepatic toxicity, but randomized trials are needed to assess its efficacy. The authors are indebted to the many physicians andnurses who take care of these patients and are facing theCOVID-19 pandemic in our country. This research wassupported by Rio Hortega contract CM19/00004 (ISCIII)(AB), and RD16/0009/0013 (ISCIII FEDER RedinRen). MJP-S is supported by a Spanish Society of Transplantscholarship |
| وصف الملف: | application/pdf |
| اللغة: | English |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cdc51c2c636a142b6db03dcb01ada0c http://hdl.handle.net/10230/52789 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....8cdc51c2c636a142b6db03dcb01ada0c |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |